
Allegra is owned by Opella, a French consumer healthcare company headquartered near Paris. Opella became a standalone company on April 30, 2025, when private equity firm Clayton, Dubilier and Rice acquired a 50 percent controlling stake. Sanofi retains 48.2 percent and French state investor Bpifrance holds 1.8 percent. Allegra is marketed in the United States by Chattem, an Opella subsidiary.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Allegra | Opella | Wholly owned |
Fexofenadine is the active metabolite of terfenadine, an earlier non-sedating antihistamine sold as Seldane. When terfenadine was found to pose cardiac risks in combination with certain other drugs, its developer, Hoechst Marion Roussel, pursued fexofenadine as a safer replacement that delivered similar efficacy without the cardiotoxicity concerns.
The FDA approved Allegra on July 25, 1996, as a prescription treatment for seasonal allergic rhinitis, later adding indications for chronic idiopathic urticaria. In 1999, Hoechst merged with the French group Rhône-Poulenc to form Aventis, headquartered in Strasbourg, moving Allegra into the Aventis portfolio. Five years later, in August 2004, Sanofi-Synthélabo acquired Aventis in one of the largest pharmaceutical takeovers of the era, and Allegra became a Sanofi product.
Sanofi positioned Allegra for a switch from prescription to over-the-counter sale, following the path Claritin had taken in 2002. In February 2010, Sanofi completed its roughly $1.9 billion acquisition of Chattem, a Chattanooga-based consumer products company with strong US retail relationships, specifically to support consumer health launches including Allegra. The FDA approved Allegra for nonprescription use, and Chattem began selling OTC Allegra in January 2011.
The Allegra family grew to include 12-hour tablets with 60 milligrams of fexofenadine, 24-hour tablets with 180 milligrams, Allegra-D combining fexofenadine with pseudoephedrine, Children's Allegra in liquid and orally disintegrating formats, and Allegra Hives for itching due to hives. A separate product line, Allegra Allergy nasal spray, does not exist; the brand remains an oral antihistamine franchise.
In 2019, Sanofi announced it would separate its consumer healthcare operations into a standalone business unit, which took the name Opella. After several years of internal separation, Sanofi announced in October 2024 that it would sell a controlling 50 percent stake in Opella to Clayton, Dubilier and Rice. The transaction closed on April 30, 2025, and Allegra transferred to the newly independent company along with the rest of the roughly 100-brand portfolio, including Doliprane, Dulcolax, Enterogermina, Essentiale, and Mucosolvan.
Since the separation, Opella has operated Allegra as one of its global allergy focus brands. The company achieved B Corp certification in April 2025, the first consumer healthcare company to do so globally, and has continued to market Allegra across North America, Europe, Latin America, and Asia-Pacific through its direct operations and Chattem's US network.
Who owns Opella?
Opella is controlled by Clayton, Dubilier & Rice, the American private equity firm that acquired a majority stake when Sanofi separated its consumer health business in April 2025. Sanofi retained a minority shareholding in the new company.
Is Opella publicly traded?
No. Opella is a private company backed by Clayton, Dubilier & Rice and has no stock listing. Unlike rivals Haleon and Kenvue, which separated via public market spin-offs, Opella was created through a private equity transaction.
How many brands does Opella own?
Opella markets approximately 100 brands across consumer health categories, including Allegra, Dulcolax, Buscopan, Doliprane, Enterogermina, Gold Bond, Icy Hot, Essentiale, Mucosolvan, and Xyzal.
Where is Opella headquartered?
Opella is headquartered in Paris, France, reflecting its origin as Sanofi's consumer healthcare division. It operates directly in 38 countries and employs more than 11,000 people.
When was Opella founded?
Opella became an independent company in April 2025, when Sanofi completed the separation of its consumer health business into the CD&R-backed standalone company. The underlying business and brands are decades older.
What is Opella's revenue?
Opella reports approximately EUR 4.6 billion in annual revenue for fiscal year 2025. As a private company, it discloses limited financial detail compared with publicly listed consumer health peers.
Opella is the first global consumer healthcare company to achieve B Corp certification, an independently verified standard administered by B Lab covering governance, worker, community, environmental, and customer impact. The certification was announced in April 2025, around the time of the company's separation from Sanofi, and applies at the corporate level across its brand portfolio including Allegra.
The company publishes an annual sustainability report covering packaging, sourcing, emissions, and access-to-health metrics. Allegra itself does not hold separate cruelty-free or vegan certifications, which is typical for over-the-counter pharmaceutical brands where regulatory requirements shape formulation and testing practices.
As a medicine containing a synthetic active pharmaceutical ingredient, Allegra is subject to pharmaceutical environmental regulations rather than food or cosmetics certification schemes. Opella's stated commitments include packaging improvements and science-based emissions targets across its manufacturing network.
Allegra has maintained a relatively clean safety record since its 1996 approval. Fexofenadine was itself developed as the safer successor to terfenadine, which was withdrawn from the US market in 1998 over cardiac arrhythmia risks when taken with certain antibiotics or grapefruit juice. Allegra's launch directly addressed that safety gap, and fexofenadine does not share terfenadine's cardiotoxicity profile.
Allegra-D contains pseudoephedrine, subject to behind-the-counter placement and purchase limits under the Combat Methamphetamine Epidemic Act. These restrictions reduce sales volume for all pseudoephedrine combination products without reflecting on the product's safety.
The most significant regulatory attention around the brand involves generic competition rather than safety. The FDA's Generic Drug User Fee program has approved multiple fexofenadine generics over the past two decades. No major branded Allegra recall has been reported as of November 2026, and routine labeling supplements continue to be approved for the product in the United States and Canada.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Bayer Ag | USA | 1993 | Mass market | Global | All Genders | |
| Kenvue | USA | 1995 | Mass market | Global | All Genders |
Healthcare PharmaceuticalsOwned by Bayer AG
Over-the-counter allergy relief brand containing loratadine, originally developed by Schering-Plough and first approved by the FDA in 1993. Owned by Bayer AG since its 2014 acquisition of Merck's consumer care business for $14.2 billion.
Healthcare PharmaceuticalsOwned by Kenvue
Over-the-counter allergy relief brand containing cetirizine hydrochloride, developed by UCB Pharma and marketed in the United States since 1995. Owned by Kenvue Inc. since its 2023 spinoff from Johnson and Johnson. Kenvue is the world's largest pure-play consumer health company by revenue, with $15.1 billion in net sales for fiscal year 2025.
Market Positioning: Allegra competes with 2 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Opella, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Bayer AG
Over-the-counter allergy relief brand containing loratadine, originally developed by Schering-Plough and first approved by the FDA in 1993. Owned by Bayer AG since its 2014 acquisition of Merck's consumer care business for $14.2 billion.
Claritin is owned by Bayer AG, a public company, a different structure than Allegra's parent.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Cresco Labs Inc.
Chicago-based cannabis company operating Sunnyside dispensaries and leading wholesale brands like Cresco, High Supply, and FloraCal.
Cresco Labs operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Nexon Pharma Sp. z o.o.
Polish dietary supplement and medical device brand owned by Nexon Pharma Sp. z o.o. of Warsaw, sold through pharmacies.
Nexon Pharma operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Haleon plc
Leading over-the-counter ibuprofen pain relief brand owned by Haleon, launched in the United States in 1984 by Whitehall Laboratories.
Advil is owned by Haleon plc, a public company, a different structure than Allegra's parent.
Healthcare PharmaceuticalsOwned by Procter & Gamble Company
American over-the-counter medication brand known for cold and flu remedies including VapoRub, DayQuil, and NyQuil. Owned by Procter & Gamble since 1985.
Vicks is owned by Procter & Gamble Company, a public company, a different structure than Allegra's parent.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.